Pulmatrix Inc Stock price
Is Pulmatrix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.
Key metrics
Pulmatrix Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Pulmatrix Inc forecast:
Analyst Opinions
7 Analysts have issued a Pulmatrix Inc forecast:
Pulmatrix Inc Events
Past Events
|
NOV
5
Q3 2026 Earnings Call
7 days ago
|
Don't miss a Thing! We will send you all news about Pulmatrix Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulmatrix Inc Stock News
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
| Head office | United States |
| CEO | Mr. Ludlum |
| Employees | 2 |
| Founded | 2015 |
| Website | www.pulmatrix.com |


